Prequalification Purpose
For an active pharmaceutical ingredient (API), WHO Prequalification is a narrower assessment than it is for a finished pharmaceutical product (FPP): it confirms the API's quality and the manufacturing site's GMP compliance, not clinical safety or efficacy — safety and efficacy are assessed at the FPP level, when a finished-product manufacturer references a prequalified API (or submits the API's master file alongside its own FPP application). This matters because API manufacturers are not submitting a safety/efficacy dossier of their own; they are demonstrating that the API is consistently manufactured to a defined quality standard under WHO GMP. Prequalified API status is a critical enabler for United Nations agencies and other international procurement bodies, and for FPP manufacturers who want to reference an already-assessed API rather than have their own dossier's API section separately assessed from scratch. It is frequently a practical prerequisite for an API to be usable in products competing in major international tenders serving resource-limited settings.
Application Requirements
API prequalification has two components: assessment of the API Master File (APIMF) against WHO norms and standards, and verification that the manufacturing site(s) comply with WHO GMP. The APIMF covers manufacturing process description, in-process controls, specifications and analytical methods, impurity profile, stability data and packaging — broadly equivalent in scope to the quality (CTD Module 3, drug substance) content of a marketing application, but without the clinical safety/efficacy modules an FPP dossier would need. Application content should be genuinely complete and internally consistent, since WHO assessors, drawing on similar review rigor to major stringent regulatory authorities, will identify and query gaps or inconsistencies much as a national regulatory authority reviewer examining a marketing application's quality section would.
Site Inspection Expectations
Prequalification includes GMP inspection of the actual manufacturing site, evaluating compliance against WHO GMP guidelines, which share substantial common ground with other major regulatory GMP frameworks while also reflecting WHO's own specific expectations and areas of particular emphasis relevant to its global health mission. Facilities pursuing prequalification should ensure genuine, sustained GMP compliance as their normal operating standard well before inspection, following the same fundamental inspection readiness principles discussed in the related FDA 483 observations article, rather than treating prequalification inspection preparation as a distinct, one-time exercise separate from genuine everyday operating practice.
Maintaining Status
Prequalified status requires ongoing maintenance, including periodic reassessment and prompt notification to WHO of any significant change to the qualified product or manufacturing site, since prequalified status reflects a point-in-time assessment that must be actively sustained through continued compliance and transparent, timely change communication rather than treated as a permanent, one-time achievement requiring no further ongoing attention. A significant undisclosed change discovered during subsequent reassessment or monitoring can jeopardize a manufacturer's prequalified status, with meaningful commercial consequences given prequalification's importance to accessing major global health procurement markets.
Relationship to National Regulatory Approval
WHO Prequalification generally operates alongside, rather than replacing, national regulatory approval in the manufacturer's own country and in countries where the product will actually be distributed, meaning prequalification represents an additional, specific qualification particularly relevant to global health procurement channels rather than a universal substitute for standard national marketing authorization requirements applicable in each individual target market.
Quality System Expectations Beyond Basic GMP Compliance
Manufacturers pursuing sustained prequalification success typically need quality systems mature enough to reliably support consistent product quality across the potentially large production volumes global health procurement demand can require, meaning prequalification readiness genuinely benefits from broader quality system maturity extending well beyond simply passing a single point-in-time inspection successfully.
Building a Sustainable Prequalification Program
Manufacturers with multiple products seeking prequalification benefit from developing genuine, sustainable internal capability specifically for navigating prequalification requirements, since the accumulated experience and quality system infrastructure built to achieve prequalification for one product genuinely support more efficient, more confident subsequent prequalification efforts for additional products going forward.
Global Health Impact Considerations
Beyond the direct commercial market access benefits, WHO Prequalification participation connects a manufacturer's quality and regulatory investment directly to genuine global public health impact, supplying essential medicines to populations that might otherwise face constrained access, a mission-oriented dimension that some manufacturers find genuinely meaningful alongside prequalification's more directly commercial market access benefits.
Leave your rating